Compare Li Auto Inc (LI) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs Sanofi SA — how do they compare? Li Auto Inc trades at $11.54 (market cap $10.71B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 8.9× Li Auto Inc's market cap, and Sanofi SA pays a 6.01% dividend while Li Auto Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Li Auto Inc for 101 Days and Sanofi SA for 94 Days on average.
| LI | SNY | |
|---|---|---|
Market Cap | $10.71B | $95.18B |
Volume | 1,781,143 | 2,995,646 |
Sector | Consumer Cyclical | Health |
52-Week High | $23.61 | $52.34 |
52-Week Low | $10.69 | $39.51 |
Typical Hold Time | 101 Days | 94 Days |
Enterprise Value | $139.58M | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $10.90, down 0.82% and near 52-week lows amid delivery moderation concerns. The stock shows bearish technical signals with negative moving averages and neutral oscillators. Fundamentally, revenue declined to $112.31B in 2025 with net income of $1.12B, though recent quarterly earnings missed expectations. Analyst sentiment is mixed with 44% buy ratings but a consensus price target of $15.18, suggesting 39% upside potential from current levels.
The outlook remains challenging with competitive pressures and cash flow concerns, but the company's strong balance sheet ($112.81B cash) provides cushion. New model launches (Li i9, MEGA) and global expansion could drive recovery, though execution risks and China's auto market weakness pose headwinds. The stock appears undervalued on P/S (0.73) and EV/EBITDA (1.72) metrics relative to growth potential.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
